Beckley Psytech will finish its trial with low-dose psilocybin in patients with a rare and debilitating headache condition, initiate a dose-ranging study on an intranasal treatment and start a Phase 2 trial for treatment-resistant depression.
Excerpt only …
READ MORE BELOW
Source : Investors appear bullish, or is it toadish, on psychedelics, pumping 0M into U.K. firm
reposted by Cannabis News World